Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Trial Profile

Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs AAV8-hFIX19 (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 11 Dec 2017 According to a Spark Therapeutics media release, Lindsey A. George, M.D. physician at Hematology at Children's Hospital of Philadelphia is the principal investigator of the trial.
    • 11 Dec 2017 According to a Spark Therapeutics media release, updated data (n=11) was presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition 2017
    • 06 Dec 2017 Interim data as of July 25, 2017 have been published in The New England Journal of Medicine, according to a Spark Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top